Medicine sales help to maintain Merck KGaA growth

14 November 2019

Growing sales in the Healthcare and Life Science business units cancelled out declines in the Performance Materials arm to keep revenue and earnings on the up at Germany’s Merck KGaA (MRK: DE) in its quarterly financial results.

Group net sales for the third quarter of 2019 were 4.05 billion euros ($4.45 billion), an increase of 8.1% on the same period of 2018, while its EBITDA pre — or earnings before interest, taxes, depreciation and amortization before one-time items — were 1.11 billion euros, up 15.4% and ahead of analysts’ average estimate of 1.06 billion euros.

Mavenclad and China key to rising sales

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK